Neogenomics vs Sotera Health
Sotera Health is the larger business, with $1.16bn of revenue in fiscal 2025 against $727m for Neogenomics (1.6 times as much). Neogenomics grew faster (10.1% against 5.7%). Sotera Health kept more of each dollar of sales as profit: a net margin of 6.7% against -14.9%.
| Latest fiscal year | NeogenomicsNEO, 2025 | Sotera HealthSHC, 2025 |
|---|---|---|
| Revenue | $727m | $1.16bn |
| Revenue growth | 10.1% | 5.7% |
| Net income | −$108m | $77.9m |
| Operating margin | — | — |
| Net margin | -14.9% | 6.7% |
| Return on equity | -12.4% | 15.4% |
| Free cash flow | −$21.8m | $149m |
| Cash | $160m | $345m |
| Total debt | $345m | $2.17bn |
| Debt to equity | — | 358.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 2,500 | 3,000 |
| Market value | $2.20bn | $4.63bn |
| Price vs our value range | — | — |
| Moat score | 34 (Weak) | 72 (Strong) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 18 sales |